- Investing.com
Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.
Metrics to compare | 300142 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300142PeersSector | |
---|---|---|---|---|
P/E Ratio | 161.9x | 35.7x | −0.5x | |
PEG Ratio | −3.24 | −0.16 | 0.00 | |
Price/Book | 2.2x | 2.5x | 2.6x | |
Price / LTM Sales | 7.9x | 7.4x | 3.3x | |
Upside (Analyst Target) | −31.4% | 5.7% | 43.5% | |
Fair Value Upside | Unlock | 12.4% | 6.9% | Unlock |